Ignite Creation Date:
2024-05-06 @ 3:28 PM
Last Modification Date:
2024-10-26 @ 1:50 PM
Study NCT ID:
NCT04648410
Status:
RECRUITING
Last Update Posted:
2023-07-27
First Post:
2020-11-26
Brief Title:
Corticosteroids in Severe COVID-19ASAP-C Study
Sponsor:
Brno University Hospital
Organization:
Brno University Hospital
Study Overview
Official Title:
Administration of Systemic Corticosteroids Among Critically Ill Patients With COVID-19 Electronic Survey ASAP-C Study
Status:
RECRUITING
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ASAP-C
Brief Summary:
Administration of systemic corticosteroids for patients with severe forms of severe acute respiratory syndromeSARS-Co-2 infection are recommended by several guidelines In the very beginning of SARS-Co-2 pandemic the early recommendation by professional organization was against routine use of corticosteroids for patients with coronavirus disease 2019 COVID-19 acute respiratory distress syndrome ARDS despite previous data and clinical practice for patients with refractory or severe form of ARDS
Detailed Description:
Administration of systemic corticosteroids for patients with severe forms of SARS-Co-2 infection are recommended by several guidelines In the very beginning of SARS-Co-2 pandemic the early recommendation by professional organization was against routine use of corticosteroids for patients with coronavirus disease 2019 COVID-19 ARDS despite previous data and clinical practice for patients with refractory or severe form of ARDS But at the latest after publication of RECOVERY trial Randomized Evaluation of Covid-19 Therapy July 2020 and ensued metaanalysis of World Health Organization WHO working group the routine administration of systemic corticosteroids was revisited However there are ongoing critical debate of the evidence regarding the dose administration timing and type of corticosteroids and ongoing randomized controlled trial RCT are challenging the recommendation of 6 mg of dexamethasone for all patients with severe form of COVID-19 The dynamic of COVID-19 surges flip-flop of official recommendations within very short period of time and ongoing critical debate could be with possible variations of daily clinical practice regarding using systemic corticosteroids In an electronic evaluation form that will be send to European Society of Intensive Care ESICM Members The electronic survey will contain 10 question In the questionnaire the participants will have to describe their routine clinical practice regarding administration of systemic corticosteroids among patients with COVID-19 ARDS
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None